Moreover, the M2-type macrophages usually have a negative role in anticancer therapy by releasing cytokines that can promote cancer progression.30 Therefore, we tested the number of M2-type macrophages in tumor by FCM with the surface marker CD11b+F4/80+CD206+. This evidence concerns the gene ITGAM and neoplasm.